Cancer related fatigue (malaise)
Conditions
Interventions
Oral intake of 5 tablets with Organic Sun Eleuthro three times a day for 14 days.
Oral intake of 30 mL with Sun Eleuthro Extract a day for 14 days.
Oral intake of 30 mL with Sun Eleuthro Extract twice
Sponsors
Health Sciences University of Hokkaido
Hokubu Rinsho Co,. Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: # Advanced cancer patient who can take food orally and whose expected survival time is more than one month. # he score of Brief Fatigue Inventory is more than 3 or more. # Age 20 years and older # Ability to provide and written informed consent. # Patients who are receiving palliative chemotherapy are eligible for study if approved by primary oncologist prior to inclusion.
Exclusion criteria
Exclusion criteria: # The patients who have taken Acanthopanax Senticosus and are not off it for more than 3 months. # Allergy to Acanthopanax Senticosus and/or honey. # Uterus and Ovary cancer patient who are histologically confirmed with estrogen receptor positive. # The patient who received Doxifluridine (FURTULON) chemotherapy. # Uncontrolled hypertension (Blood pressure more than 180/90 mmHg) # Currently taking digoxin formulation. # Co-existence of severe complication. # Pregnant or expected to be pregnant, and breast feeding mother. # Co-existence of endometriosis and myoma uteri. # Unable to provide and written informed consent due to mental disorder. # Concomitant use of drugs which is contraindicated towards Acanthopanax Senticosus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of the patient whose BFI and FACIT-F can be evaluated at day 28. | — |
Secondary
| Measure | Time frame |
|---|---|
| # The changes in BFI score during registration and day 29. # The changes in FACIT-F subscale score during registration and day 29. # The changes in FACIT-F total score during registration and day 28. # Safety (The frequency of total adverse event). # General condition (assessed by ECOG-PS). # The changes in laboratory data. | — |
Countries
Japan
Contacts
Public ContactTada Masahito
Higashi Sapporo Hospital Administrative department
Outcome results
None listed